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Abstract
Background: Costello syndrome is a rare syndrome of multiple congenital anomalies. The typical clinical traits include
dysmorphic craniofacial features, skin hyperpigmentation and excess, feeding difficulties leading to severe postnatal
growth retardation, short stature, joint hypermobility, and delayed psychomotor development. Additionally, Costello
syndrome may present with an increased incidence of congenital heart disease, hypertrophic cardiomyopathy, and
increased risk of both benign and malignant tumors. Furthermore, cases of patients with endocrine disorders such as
adrenal insufficiency and endogenous growth hormone deficiency have also been documented.
Case presentation: We present a patient with Costello syndrome who has been successfully treated with
recombinant human growth hormone (rhGH) for almost 4 years.
Conclusions: The possibility of growth hormone (GH) treatment can be considered in cases of documented GH
deficiency in patients with Costello syndrome, but only under close oncologic and cardiologic supervision.
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Background
Costello syndrome (CS, OMIM #218040) is caused by het-
erozygous germline mutations in the proto-oncogene HRAS
that cause dysfunction of the Ras-MAPK signaling pathway.
To date, 15 mutations in HRAS have been identified. The
birth prevalence of this disease is estimated at 1:1,230,000 to
1:300,000 [1–4]. Clinically, CS is characterized by poly-
hydramnios, high birth weight, postnatal growth retardation,
relative macrocephaly, coarse facial features, loose skin,
especially of the hands and feet, hyperpigmentation,
hypertrophic cardiomyopathy, atrial arrhythmias, papillo-
mata, developmental delay or mental retardation, and pre-
disposition to malignancies. In the newborn and neonatal
periods, the presence of suggestive facies and severe feeding
difficulties leading to failure to thrive and hypoglycemia help
make the correct diagnosis [5–7]. Furthermore, cases of
Costello syndrome patients with endocrine disorders such
as adrenal insufficiency and endogenous growth hormone de-
ficiency have also been documented in the literature [8–11].
Due to the complex nature of the discussed syndrome, pa-
tients require multidisciplinary care (provided by cardiologists,
speech therapists, gastroenterologists, orthopedic surgeons)
along with early stimulation and developmental support.
Because of the short stature and growth hormone deficiency
in this condition, growth hormone therapy is often consid-
ered. For decades there has been great debate on the
anticipated risk of carcinogenesis and cardiomyopathy
weighted against the potential benefits resulting from
recombinant human growth hormone (rhGH) therapy. To
date, there are no conclusive data showing a negative role of
rhGH therapy in the development of these diseases.
Here we report a six-year-old patient with Costello
syndrome, who has been successfully treated with rhGH
for 42 months.
Case presentation
AM, was born at 40 weeks gestation by caesarean sec-
tion (due to large fetal mass) as the first baby of healthy
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and nonconsanguineous parents with a birth weight of
4270 g (>97 c), length of 55 cm (50 c) and head circum-
ference of 38 cm (>97c). Her Apgar score was 7/7/8
points. The pregnancy was complicated by polyhydram-
nios and impaired glucose tolerance in the mother.
In the neonatal period, generalized edema, hypoglycemia,
and hypocalcaemia were observed. Transthoracic echocar-
diography revealed thickened muscles of both ventricles
and septum, although follow-up cardiac examinations re-
vealed no evidence of cardiomyopathy.
During the first two years of life the child was repeat-
edly hospitalized due to a number of problems (the clin-
ical symptoms observed in the patient are presented in
Table 1). At the age of 8 weeks the girl was evaluated
due to failure to thrive. Physical examination revealed:
poorly developed subcutaneous tissue with excess skin
(this was attributed to resolution of edema), reduced
muscle tone, and enlarged liver. Laboratory tests did not
find evidence of hypothyroidism or inborn errors of me-
tabolism. Ultrasonography followed by gastric scintiscan
and upper GI series revealed hiatal hernia and gastric
endoscopy, the latter being the base for a diagnosis of
gastroesophageal reflux. Additionally, the 24-h esopha-
geal pH study was conducted, to further help with diag-
nosis, yielding inconsistent results that were borderline
normal. At the age of four months the patient mani-
fested psychomotor delay, joint laxity, variable muscle
tone, and hyperactive knee reflexes. Follow-up cardiac
examinations revealed no signs of cardiomyopathy, but
complex premature ventricular and supraventricular
contractions and sinus arrest were present. She required
treatment with amiodarone, which was withdrawn after
one month. No cardiac arrhythmias were shown in sub-
sequent 24-h-Holter monitoring.
The treatment of gastroesophageal reflux, which involved
proton pump inhibitors and prokinetic agents, was ineffect-
ive. During eight months, her weight gain had been only
1000 g. At the age of nine months the patient weighed
5300 g (SD: −4.92). Due to persistent feeding difficulties she
was referred for surgical treatment and Nissen fundoplica-
tion was performed at the age of 11 months. The improve-
ment after abovementioned procedure was very brief, with
feeding difficulties quickly reoccurring. Due to lack of im-
provement after pharmacological treatment, and persistent
signs of gastroesophageal reflux in performed endoscopy
our patient was qualified for second operation. Finally the
decision about surgical treatment was abandoned due to
slow spontaneous improvement in feeding and apetite after
the patient was 3 years old.
At the age of 2 years and 9 months Costello syndrome
was suspected on the basis of phenotypic traits (large
mouth, wide lips, short nasal bridge, loose skin deeply
fissured on the palms and soles of the feet, joint laxity,
and abnormal feet position, Fig. 1) and case history. The
diagnosis was confirmed by molecular tests, which iden-
tified c.35G > C (p.G12A) substitution in the HRAS
gene, the second most common mutation responsible
for Costello syndrome. Molecular studies in both par-
ents revealed that this mutation occurred de novo [3, 4].
The investigation of delayed growth was performed at
the age of 3 years and 2 months. Physical examination
noted significantly short stature, i.e., a height of 84 cm
(SD: −4.33), and underweight, 10.7 kg (SD: −2.86). Rou-
tine laboratory tests did not show any abnormalities.
Electrocardiographic examination and abdominal ultra-
sound were normal. Hormone analysis revealed normal
thyroid function, normal daily cortisol profile and
rhythm. Reduced levels of insulin-like growth factor 1 in
relation to chronological age were detected (26,3 ng/ml,
normal level range at this age 49–289 ng/ml). Bone age
was found to be consistent with the chronological age.
Growth hormone levels did not reach normal values in
the nocturnal secretion test or in L-Dopa and clonidine
stimulation tests (maximum secretion: 8 ng/ml), see
Table 2 for details. Based on the above findings and clin-
ical observations, partial endogenous growth hormone
deficiency was established.
At the age of 3 years and 9 months the girl was quali-
fied for growth hormone therapy, following careful con-
siderations of the risks and benefits and discussion of
the issue with the child’s parents.
Growth hormone was administered by subcutaneous in-
jection once daily, in the evening, at a dose of 0.031 mg/
kg/day. Initially, the check-up visits in the Department
were held every three months, and then every six months.
The following issues were evaluated: response to treat-
ment, tolerability, and laboratory test results, with particu-
lar emphasis on carbohydrate metabolism and bone age
progression (Table 3).
During the initial check-ups, significant acceleration of
growth was recorded. Throughout the first year of
treatment, her growth rate was 9.49 cm/year, and in the
next two years it was 12.36 cm/year and 7.71 cm/year,
respectively, while during the pretreatment period her
average growth rate was 4.28 cm/year. The curves of the
patient's body weight and height gain before and during
rhGH treatment are shown in Fig. 2a and b.
During the treatment, progression of the abnormalities
within the ligaments of the ankles and hip joints (right
club foot, left plano-valgus foot, shortening of the
Achilles tendon, dislocation of the right hip) was ob-
served. At the age of 5 years and 6 months, surgical cor-
rection of both feet was necessary due to further
progression of mobility impairment, and plasty of the hip
joint was performed in the following year. At present, the
patient is recovering after the last intervention.
Currently, after 42 months of rhGH treatment, the girl
has grown 30.3 cm, reaching a body height above the 3rd
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percentile (115 cm; SD: −1.61), her weight gain has been
10.4 kg. Her current weight is 20.3 kg (10–25 percentile;
SD: −1.28). So far, no serious adverse events have been
observed. The patient tolerates daily injections of growth
hormone well, she receives comprehensive speech ther-
apy and rehabilitation, and attends kindergarten. Her
parents have observed a significant improvement in her
psychomotor development, especially with respect to
speech.
Discussion
Costello syndrome was first described in 1977 by Jack
Costello, a New Zealand pediatrician, in two unrelated
children who presented similar phenotypic characteris-
tics. The molecular etiology of this syndrome (germline
mutations in the HRAS gene) was identified in 2005 [2].
Among many dysfunctions associated with this condi-
tion, impaired growth is one of the most challenging
clinical problems [8, 12, 13]. The average final height in
Costello syndrome patients, without growth-stimulating
therapy, reaches about 138 cm (118–148 cm) [7]. The
pathogenesis of short stature associated with this condi-
tion has been studied in recent decades. The first cases
diagnosed with partial/total endogenous growth hor-
mone deficiency and treated with rhGH were described
in the 1990s [9–11]. To date, there are few studies in the
scientific literature that assess the safety and efficacy of
rhGH therapy in individual patients [14, 15]. As the syn-
drome is extremely rare, evaluating a larger group of pa-
tients iseems to be a very difficult task. Increased
incidence of cancer and increased risk of development
of hypertrophic cardiomyopathy are serious clinical
problems that should be taken into account when
considering treatment with rhGH [1, 7, 8, 15]. Gripp et
al. [5] estimated that the risk of developing tumors in
patients with Costello syndrome reaches 17 %, most of
which are rhabdomyosarcoma, neuroblastoma, papil-
loma, and bladder cancer. Interestingly, the p.G12A mu-
tation detected in our patient is the main mutation
associated with the higher risk of cancer in CS, which
correlates with an up to 57 % risk in affected patients (2,
3). However, no occurrence of malignancy has been
noted in the patient so far. Growth hormones promote
cell divisions, which may generate a potential hazard.
However, existing research in this area has given incon-
clusive results [14, 15]. Stein et al. [13] presented long-
term observations involving three patients with en-
dogenous growth hormone deficiency successfully
treated with rhGH with no severe adverse events. On
the other hand, cases of patients with unsatisfactory re-
sponse to rhGH therapy [9] and complications during
the treatment have also been documented. There are re-
ports describing a case of a 16-year-old girl diagnosed
with bladder cancer after 7 years of rhGH therapy [16], a
26-month-old boy diagnosed with rhabdomyosarcoma
after one year of treatment [14], and progression of
hypertrophic cardiomyopathy in a 6-year-old boy treated
with rhGH [17]. However, in all of these cases it is diffi-
cult to assess whether the administration of growth hor-
mone actually influenced the development of these
diseases and to what extent.
During 3.5 years of follow-up, we have observed accel-
erated growth in our rhGH-treated patient, and no ser-
ious health complications have yet occurred. In infancy
the girl was diagnosed with supraventricular arrhythmias
and hypertrophic cardiomyopathy, which was not con-
firmed in subsequent echocardiography. However, be-
cause of the risk of recurrence she remains under the
systematic control of a cardiologist. The observed
motor-system problems, resulting from the excessive
ligamentous laxity associated with Costello syndrome,
were already present before the initiation of growth hor-
mone therapy. It seems that their progression was asso-
ciated with significant growth acceleration resulting
Fig. 1 The presented 6-year-old girl with Costello syndrome after 30 months of treatment with rhGH. The pictures show typical phenotypic
features of the syndrome: loose skin with deep palmar creases (a); abnormal feet position as a result of excessive joint laxity (b)
Table 2 Growth hormone secretion in nocturnal and
stimulation tests
0’ 30’ 60’ 90’ 120’ 150’
Nocturnal GH excretion [ng/ml] 4,4 2,1 0,8 1,7 2,0 1,9
GH after L-dopa [ng/ml] 0,94 0,99 1,1 1,3 1,2 0,88
GH after clonidine [ng/ml] 0,91 0,96 5,2 8,0 4,0 2,5
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from GH supply, but the impact of rhGH therapy alone
is difficult to assess.
Conclusions
The available data, based on a small number of reported
cases of Costello syndrome treated with recombinant
growth hormone, do not allow drawing general
conclusions. The very good response to the treatment,
demonstrated in our case, improved her body height
prognosis and eliminated the disability related to ex-
treme short stature. The 3.5-year observation revealed
no serious side effects. However, reports of the other-
authors regarding the development and progression of
cancer and hypertrophic cardiomyopathy in children
Table 3 Selected auxological parameters of the patient during rhGH treatment
















3 years and 2 months 84 −4.94 2.10 10.7 −2.86 15.2 −0.504
3 years 9 months
(start of rhGH treatment)
84.7 −4.92 0.80 12.1 −2.60 16.9 1.005 3 years
4 years 88.9 −3.48 16.80 12.1 −2.58 15.3 0.02
4 years 5 months 92 −3.29 7.44 13.3 −2.41 15.7 0.496
4 years 8 months 93.3 −3.31 7.40 14 −2.28 16.1 0.508 4 years 2 months
5 years 2 months 97.8 −2.84 5.20 15.4 −1.80 16.1 0.507
5 years 6 months 103 −2.02 9.00 16 −1.77 15.1 0.475 5 years – 5 years 9 months
6 years 1 month 107.5 −1.67 13.00 19 −0.92 16.4 0.511
6 years 8 months 109 −1.78 2.57 a 18.4 −1.46 15.5 0.480 7 years 10 months
7 years 2 months 115 −1.61 12.00 20.3 −1.28 15.3 0.466
aInterruptions in rhGH administration caused by orthopedic treatment
Fig. 2 The course of growth (a) and weight gain (b) in the patient before and during rhGH treatment
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with Costello syndrome treated with rhGH indicate that
these patients require special oncologic and cardiologic
supervision.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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